Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Chris Ryan
Articles
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 28th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
Latest Updated Articles
Published: October 23rd 2024 | Updated: October 24th 2024
What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders
Published: January 18th 2016 | Updated: October 18th 2024
10 Pharmacy Quotes That Will Make You Rethink the Profession
Published: September 22nd 2015 | Updated: October 14th 2024
Gabapentin Differs From Pregabalin in Several Key Ways
Published: May 24th 2024 | Updated: November 18th 2024
Thinking Outside The Pill Bottle: Forging Your Own Path
Published: October 22nd 2024 | Updated: November 18th 2024
Patients With Endometriosis Have an Increased Risk of Developing Cardiovascular Disease
Published: September 23rd 2024 | Updated: November 18th 2024
From Statins to PSCK9 Inhibitors: Choosing the Right Therapy for Cholesterol
